AKESO INC. O.N. Net Assets
AKESO INC. O.N. net assets. Based on the latest financial reports, AKESO INC. O.N. (4RY) has net assets worth €8.95 Billion EUR (≈ $10.46 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€16.00 Billion ≈ $18.71 Billion USD) and total liabilities (€7.05 Billion ≈ $8.25 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4RY year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.95 Billion |
| % of Total Assets | 55.91% |
| Annual Growth Rate | 28.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 36.37 |
Net Assets of AKESO INC. O.N. (2021–2025)
Net assets of AKESO INC. O.N. from 2021 to 2025. This chart illustrates how AKESO INC. O.N.'s net assets have evolved over time, based on quarterly financial data. See AKESO INC. O.N. balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for AKESO INC. O.N. (2021–2025)
The table below shows the annual net assets of AKESO INC. O.N. from 2021 to 2025. For live market cap and overall valuation, see 4RY market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €8.95 Billion ≈ $10.46 Billion |
+32.46% |
| 2024-12-31 | €6.75 Billion ≈ $7.90 Billion |
+49.45% |
| 2023-12-31 | €4.52 Billion ≈ $5.28 Billion |
+77.35% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
-22.32% |
| 2021-12-31 | €3.28 Billion ≈ $3.83 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AKESO INC. O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72079800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
AKESO INC. O.N. Net Assets Breakdown (December 2025)
AKESO INC. O.N. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €12.52 Billion | 138.35% |
| Total Equity | €9.05 Billion | 100.00% |
AKESO INC. O.N. Competitors by Market Cap
The table below lists competitors of AKESO INC. O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orkla ASA
OL:ORK
|
$9.91 Billion |
|
JSW Energy Limited
NSE:JSWENERGY
|
$9.92 Billion |
|
Medibank Private Ltd
AU:MPL
|
$9.92 Billion |
|
Service Corporation International
NYSE:SCI
|
$9.92 Billion |
|
Discovery Holdings Ltd
JSE:DSY
|
$9.89 Billion |
|
Knight Transportation Inc
NYSE:KNX
|
$9.89 Billion |
|
Groep Brussel Lambert NV
BR:GBLB
|
$9.89 Billion |
|
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
|
$9.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AKESO INC. O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,813,953,000 to 9,047,894,000, a change of 2,233,941,000 (32.8%).
- Net loss of 1,113,025,000 reduced equity.
- New share issuances of 3,205,262,000 increased equity.
- Other factors increased equity by 141,704,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.11 Billion | -12.3% |
| Share Issuances | €3.21 Billion | +35.43% |
| Other Changes | €141.70 Million | +1.57% |
| Total Change | €- | 32.78% |
Book Value vs Market Value Analysis
This analysis compares AKESO INC. O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.37x to 0.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.87 | €9.19 | x |
| 2022-12-31 | €3.13 | €9.19 | x |
| 2023-12-31 | €5.58 | €9.19 | x |
| 2024-12-31 | €7.59 | €9.19 | x |
| 2025-12-31 | €9.82 | €9.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AKESO INC. O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36.42%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.77x
- Recent ROE (-12.30%) is below the historical average (-10.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -33.97% | -476.42% | 0.05x | 1.52x | €-1.39 Billion |
| 2022 | -44.33% | -139.48% | 0.15x | 2.09x | €-1.43 Billion |
| 2023 | 43.23% | 44.81% | 0.49x | 1.96x | €1.56 Billion |
| 2024 | -7.55% | -24.22% | 0.17x | 1.87x | €-1.20 Billion |
| 2025 | -12.30% | -36.42% | 0.19x | 1.77x | €-2.02 Billion |
Industry Comparison
This section compares AKESO INC. O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AKESO INC. O.N. (4RY) | €8.95 Billion | -33.97% | 0.79x | $9.89 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more